20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Results of the MOVES-PD trial announced
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson’s patients who have a GBA-1 gene mutation. Sanofi designed the venglustat clinical trial to assess changes in the course of the disease.
Further data on the relationship between diabetes and Parkinson’s
New research has found that there is convincing evidence that Type 2 diabetes is associated with a greater risk of Parkinson’s, but may in turn allow for better management of the disease.
Rheumatoid arthritis and Parkinson’s
Recently, researchers have asked whether there is an association between Parkinson’s and rheumatoid arthritis: Could people with rheumatoid arthritis be at higher risk of developing Parkinson’s?
COVID-19 and the need for remote clinical trials
Whilst the COVID pandemic has dealt a cruel blow to current Parkinson’s research efforts, it has served as an opportunity for innovation and improvement, and this is particularly so in the way some clinical trials are being organised.
More data from the ‘Blue Rockers’
BlueRock Therapeutics has published two preclinical research reports outlining the cell culturing method that they are taking into clinical trials.